Literature DB >> 23856911

Recent progress in pancreatic cancer.

Christopher L Wolfgang1, Joseph M Herman, Daniel A Laheru, Alison P Klein, Michael A Erdek, Elliot K Fishman, Ralph H Hruban.   

Abstract

Pancreatic cancer is currently one of the deadliest of the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and less invasive than ever, novel drug combinations have been shown to improve survival, advances in radiation therapy have resulted in less toxicity, and enormous strides have been made in the understanding of the fundamental genetics of pancreatic cancer. These advances provide hope but they also increase the complexity of caring for patients. It is clear that multidisciplinary care that provides comprehensive and coordinated evaluation and treatment is the most effective way to manage patients with pancreatic cancer.
Copyright © 2013 American Cancer Society, Inc.

Entities:  

Keywords:  medical oncology; molecular biology; pancreatic neoplasms; radiation oncology; radiology

Mesh:

Year:  2013        PMID: 23856911      PMCID: PMC3769458          DOI: 10.3322/caac.21190

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  230 in total

1.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

Review 2.  Clinical importance of precursor lesions in the pancreas.

Authors:  Ralph H Hruban; Kyoichi Takaori; Marcia Canto; Elliot K Fishman; Kurtis Campbell; Kieran Brune; Scott E Kern; Michael Goggins
Journal:  J Hepatobiliary Pancreat Surg       Date:  2007-05-29

3.  EUS-guided pancreatic fluid aspiration for DNA analysis of KRAS and GNAS mutations for the evaluation of pancreatic cystic neoplasia: a pilot study.

Authors:  Ali A Siddiqui; Thomas E Kowalski; Ramalinga Kedika; Abhik Roy; David E Loren; Eric Ellsworth; Douglas Adler; Sydney D Finkelstein
Journal:  Gastrointest Endosc       Date:  2013-04       Impact factor: 9.427

Review 4.  The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.

Authors:  Richard L Wahl; Joseph M Herman; Eric Ford
Journal:  Semin Radiat Oncol       Date:  2011-04       Impact factor: 5.934

5.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

6.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

Review 7.  Pancreatic intraepithelial neoplasia revisited and updated.

Authors:  B Sipos; S Frank; T Gress; S Hahn; G Klöppel
Journal:  Pancreatology       Date:  2008-12-12       Impact factor: 3.996

8.  18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy.

Authors:  Devin Schellenberg; Andy Quon; A Yuriko Minn; Edward E Graves; Pamela Kunz; James M Ford; George A Fisher; Karyn A Goodman; Albert C Koong; Daniel T Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-07       Impact factor: 7.038

9.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

Authors:  William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

10.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

View more
  359 in total

1.  The crown jewelry of the surgeries for pancreatic cancer.

Authors:  Lei Zheng; Taiping Zhang
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

2.  Pancreatic Cancer: a Challenge to Cure.

Authors:  M Tewari
Journal:  Indian J Surg       Date:  2015-10-19       Impact factor: 0.656

Review 3.  Current progress in immunotherapy for pancreatic cancer.

Authors:  Kelly Foley; Victoria Kim; Elizabeth Jaffee; Lei Zheng
Journal:  Cancer Lett       Date:  2015-12-23       Impact factor: 8.679

Review 4.  Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids.

Authors:  Taisuke Imamura; Shuhei Komatsu; Daisuke Ichikawa; Tsutomu Kawaguchi; Mahito Miyamae; Wataru Okajima; Takuma Ohashi; Tomohiro Arita; Hirotaka Konishi; Atsushi Shiozaki; Ryo Morimura; Hisashi Ikoma; Kazuma Okamoto; Eigo Otsuji
Journal:  World J Gastroenterol       Date:  2016-07-07       Impact factor: 5.742

Review 5.  Cancer stem cells: involvement in pancreatic cancer pathogenesis and perspectives on cancer therapeutics.

Authors:  Cristiana Pistol Tanase; Ana Iulia Neagu; Laura Georgiana Necula; Cristina Mambet; Ana-Maria Enciu; Bogdan Calenic; Maria Linda Cruceru; Radu Albulescu
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

6.  NF45 overexpression is associated with poor prognosis and enhanced cell proliferation of pancreatic ductal adenocarcinoma.

Authors:  Chunhua Wan; Chen Gong; Li Ji; Xiaorong Liu; Yayun Wang; Liang Wang; Mengting Shao; Linlin Yang; Shaoqing Fan; Yin Xiao; Xiaotong Wang; Manhua Li; Guoxiong Zhou; Yixin Zhang
Journal:  Mol Cell Biochem       Date:  2015-08-15       Impact factor: 3.396

7.  Glycogen synthase kinase-3β ablation limits pancreatitis-induced acinar-to-ductal metaplasia.

Authors:  Li Ding; Geou-Yarh Liou; Daniel M Schmitt; Peter Storz; Jin-San Zhang; Daniel D Billadeau
Journal:  J Pathol       Date:  2017-07-27       Impact factor: 7.996

Review 8.  Road map for pain management in pancreatic cancer: A review.

Authors:  Marie José Lahoud; Hampig Raphael Kourie; Joelle Antoun; Lana El Osta; Marwan Ghosn
Journal:  World J Gastrointest Oncol       Date:  2016-08-15

9.  The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma.

Authors:  Ling Ma; Xiaodong Tian; Feng Wang; Zhengkui Zhang; Chong Du; Xuehai Xie; Marko Kornmann; Yinmo Yang
Journal:  Cancer Biol Ther       Date:  2016-08-29       Impact factor: 4.742

10.  Growth inhibition and apoptosis induction by alternol in pancreatic carcinoma cells.

Authors:  Pei-Fang Cong; Ying-Chun Qu; Jie-Peng Chen; Li-Li Duan; Cheng-Jiang Lin; Xiao-Lin Zhu; Jesse Li-Ling; Mei-Xia Zhang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.